GLOW

BPC-157 is a synthetic 15-amino-acid sequence derived from a protein found in human gastric juice, studied in published animal and in-vitro work since the early 1990s. The most replicated theme is connective-tissue repair: in a frequently cited in-vitro study (Chang et al., J Appl Physiol 2011), cultured Achilles-tendon fibroblasts exposed to BPC-157 at 0.5-2 µg/mL showed concentration-dependent increases in cell migration and survival, with the authors implicating the FAK-paxillin pathway. A 2019 review (Gwyer et al., Cell Tissue Res) catalogued preclinical reports across tendon, ligament, muscle, and bone models. Important framing for researchers: this body of evidence is preclinical — the authors themselves note the absence of human clinical trials, and findings in animal models do not establish human outcomes.

TB-500 is a synthetic fragment corresponding to an active region of thymosin β4, a naturally occurring actin-binding peptide. Where the BPC-157 literature centers on localized repair, the thymosin β4 literature is studied more in terms of systemic processes — cell migration, angiogenesis, and survival signaling. Bock-Marquette et al. (Nature 2004) reported that thymosin β4 promoted cardiac-cell migration and survival via integrin-linked kinase in animal injury models, and reviews by Goldstein (2005) and Philp & Kleinman (2010) summarize dermal, corneal, and cardiac repair endpoints across preclinical work. This complementary local-plus-systemic framing is the stated rationale researchers give for studying the two peptides as a pair.

GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a sequence whose plasma concentration declines with age. The published literature (Pickart & Margolina, Int J Mol Sci 2018; Pickart et al., 2015) associates GHK-Cu in laboratory and animal models with skin-matrix remodeling, antioxidant signaling, and modulation of a broad set of genes related to tissue maintenance. In a blend context it is studied as the cosmetic/dermal-remodeling component alongside the BPC-157/TB-500 repair pair.

Because some preclinical reports associate BPC-157 with angiogenic signaling (e.g., VEGFR2 pathway involvement; Seiwerth et al., 2018), a recurring question in the research community is whether that activity could be undesirable in the context of existing tumors. The honest state of the evidence: there is no human study linking BPC-157 to tumor formation, and the angiogenesis discussion is drawn from animal and cell models. Nothing here should be read as a safety assurance. This page does not claim BPC-157 is safe, and any work involving subjects with cancer or other active disease is a question for a qualified clinician — not a peptide page. Regulatory note: the FDA placed BPC-157 in a category restricting compounding in 2024; this material is provided strictly for laboratory-research context.

Catalog format: lyophilized research material as presented on the storefront listing.

In-stock listing sizes: Standard.

Laboratory handling note: publications in this field typically report controlled storage, chain-of-custody documentation, and method-specific reconstitution procedures under institutional SOPs. This site does not provide dosing, administration, or protocol instructions.